Adrenal cortical carcinoma is a rare and aggressive cancer with poor prognosis. Cases usually present with signs and symptoms of excessive hormone production. Hyperglycemia and Cushing syndrome are common, but tumor-associated hypoglycemia due to paraneoplastic secretion of insulin-like growth factor-2 (termed Anderson's syndrome) is uncommon. Given the rarity of adrenal cortical carcinoma, diagnosis and management of associated complications is challenging. In this study, we present a case of metastatic adrenal cortical carcinoma with a myriad of hormonal abnormalities. We will also briefly review literature regarding genetic association, pathophysiology, treatment options, and prognosis.
Get full access to this article
View all access options for this article.
References
1.
KebebewE, ReiffE, DuhQ-Y, et al.Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?. World J Surg. 2006; 30(5):872–8.
2.
AudenetF, MéjeanA, Chartier-KastlerE, RouprêtM. Adrenal tumours are more predominant in females regardless of their histological subtype: a review. World J Urol. 2013; 31(5):1037–43.
3.
ElseT, KimAC, SabolchA, et al.Adrenocortical carcinoma. Endocr Rev. 2014; 35(2):282–326.
4.
LutonJP, CerdasS, BillaudL, et al.Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med. 1990; 322(17):1195–201.
IshikuraK, TakamuraT, TakeshitaY, et al.Cushing's syndrome and big IGF-II associated hypoglycaemia in a patient with adrenocortical carcinoma. BMJ Case Rep. 2010; 2010:bcr07.2009.2100.
7.
DaughadayWH, EmanueleMA, BrooksMH, et al.Synthesis and secretion of insulin-like growth factor II by a leiomyosarcoma with associated hypoglycemia. N Engl J Med. 1988; 319(22):1434–40.
8.
SchovanekJ, CibickovaL, CtvrtlikF, et al.Hypoglycemia as a symptom of neoplastic disease, with a focus on insulin-like growth factors producing tumors. J Cancer. 2019; 10(26):6475–80.
9.
ParagliolaRM, CorselloA, LocantoreP, et al.Medical approaches in adrenocortical carcinoma. Biomedicines. 2020; 8(12):551.
10.
AbivenG, CosteJ, GroussinL, et al.Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab. 2006; 91(7):2650–5.
11.
IglesiasP, DíezJJ. Management of endocrine disease: a clinical update on tumor-induced hypoglycemia. Eur J Endocrinol. 2014; 170(4):R147–57.
12.
DynkevichY, RotherKI, WhitfordI, et al.Tumors, IGF-2, and hypoglycemia: insights from the clinic, the laboratory, and the historical archive. Endocr Rev. 2013; 34(6):798–826.
13.
FassnachtM, JohanssenS, QuinklerM, et al.Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer. 2009; 115(2):243–50.
14.
NiemanLK, BillerBMK, FindlingJW, et al.The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008; 93(5):1526–40.
15.
ArltW, BiehlM, TaylorAE, et al.Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. J Clin Endocrinol Metab. 2011; 96(12):3775–84.
16.
SongG, JoeBN, YehBM, et al.Risk of catecholamine crisis in patients undergoing resection of unsuspected pheochromocytoma. Int Braz J Urol. 2011; 37(1):31–5.
17.
ZografosGC, DriscollDL, KarakousisCP, HubenRP. Adrenal adenocarcinoma: a review of 53 cases. J Surg Oncol. 1994; 55(3):160–4.
18.
BilimoriaKY, ShenWT, ElarajD, et al.Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer. 2008; 113(11):3130–6.
19.
SchteingartDE, DohertyGM, GaugerPG, et al.Management of patients with adrenal cancer: recommendations of an International Consensus Conference. Endocr Relat Cancer. 2005; 12(3):667–80.
20.
FassnachtM, TerzoloM, AllolioB, et al.Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012; 366(23):2189–97.
21.
BodnarTW, AcevedoMJ, PietropaoloM. Management of non-islet-cell tumor hypoglycemia: a clinical review. J Clin Endocrinol Metab. 2014; 99(3):713–22.
